In a recent study, published in The Journal of Neuroscience, researchers adopted a novel approach to dyskinesia by treating it as a “bad motor memory.”
They discovered that inhibiting a protein called Activin A could stop dyskinesia symptoms and essentially erase the brain’s “bad memory” response to certain Parkinson’s therapies.
Rather than seeking an entirely new treatment, researchers aimed to find a way to prevent dyskinesia from developing in the first place.
So what is the role of this molecule and does it play role in other brain and neurological functions, or just the one? (Meaning: am I going to lose mentation as the cost for the benefit of reducing dyskinesia?) and who does it benefit, and who does it not benefit?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.